{"id":"W4225291722","doi":"10.1016/j.ejca.2022.03.029","title":"Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Avelumab; Neuroendocrine tumors; Internal medicine; Gastroenterology; Progressive disease; Oncology; Surgery; Clinical trial; Chemotherapy; Immunotherapy; Cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008729663,0.0006347023,0.001335553,0.0002684196,0.0001569556,0.0008741319,0.0003426951,0.000478414,0.00269886],"category_scores_gemma":[0.0008767566,0.0001853176,0.001309408,0.0002779178,0.0003986896,0.0009680479,0.0002599402,0.002002704,0.0005348185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006724159,"about_ca_system_score_gemma":0.0004866363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006539205,"about_ca_topic_score_gemma":0.003370759,"domain_scores_codex":[0.9997995,0.00007927081,0.00001266845,0.00003161621,0.00002801236,0.00004896782],"domain_scores_gemma":[0.9996927,0.00009754223,0.00005413765,0.00002136913,0.00002292157,0.0001114739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.311696,0.005713492,0.01198942,0.005026006,0.007672585,0.0003425776,0.0002743001,0.006388878,0.02161636,0.001502554,0.01519491,0.6125829],"study_design_scores_gemma":[0.5710252,0.2364282,0.07727716,0.001625106,0.01372534,0.002293671,0.0005026936,0.009253796,0.01417184,0.004125508,0.06933438,0.0002370886],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9377143,0.04858393,0.0006971631,0.001826222,0.0005641861,0.0003286811,0.001862604,0.0001395368,0.008283395],"genre_scores_gemma":[0.9687889,0.02000735,0.001019658,0.001343219,0.00029721,0.0002847988,0.003187792,0.00004370527,0.005027452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00269886,"threshold_uncertainty_score":0.009028614,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05478826897775532,"score_gpt":0.3568576852568895,"score_spread":0.3020694162791342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}